Harrow (HROW) Income from Continuing Operations (2010 - 2026)
Harrow's (HROW) quarterly Income from Continuing Operations came in at 27602000.0 in Q1 2026, down 55.24% year-on-year from 61669208.34 in Q1 2025, and down 365.48% quarter-over-quarter from 10397000.0 in Q4 2025.
Harrow (HROW) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Harrow's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 27602000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 55.24% year-over-year to 27602000.0 in Q1 2026; TTM through Mar 2026 was 11190000.0, a 48.42% increase from a year earlier, with the FY2025 full-year figure at 5139000.0, up 70.6% from the prior year.
- Income from Continuing Operations fell to 27602000.0 in Q1 2026 per HROW's latest filing, from 10397000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10397000.0 in Q4 2025 and bottomed at 27602000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 4391000.0 (2023), against an average of 4996941.18.
- Across the five-year window, Income from Continuing Operations plunged 1223.5% in 2022 and surged 177.17% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 1055000.0 in 2022, then plunged by 967.11% to 9148000.0 in 2023, then surged by 174.08% to 6777000.0 in 2024, then surged by 53.42% to 10397000.0 in 2025, then plunged by 365.48% to 27602000.0 in 2026.
- Per Business Quant, the three latest HROW Income from Continuing Operations figures stand at 27602000.0 (Q1 2026), 10397000.0 (Q4 2025), and 1020000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | -27.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.33 Mn |
| Jun 30, 2021 | -2.48 Mn |